Recursion Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-11-05
- Employees
- 500
- Market Cap
- $2.1B
- Website
- http://www.recursion.com
- Introduction
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Recursion Announces Two Key Investigational Oncology Advances
Recursion announced MHRA and FDA clearances for Phase 1 trials of REC-3565, a MALT1 inhibitor for B-cell malignancies, and REC-4539, a reversible LSD1 inhibitor for small-cell lung cancer. REC-3565 aims to reduce hyperbilirubinemia risk, while REC-4539 targets brain metastases. Both drugs represent advancements in precision medicine.
Recursion Announces Two Key Investigational Oncology Developments
Recursion announced MHRA and FDA clearances for clinical trials of REC-3565, a MALT1 inhibitor for B-cell malignancies, and REC-4539, a reversible LSD1 inhibitor for small-cell lung cancer. REC-3565 aims to reduce hyperbilirubinemia risk, while REC-4539 targets brain metastases. Both drugs represent advancements in precision oncology.
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.6% – Here’s What Happened
Recursion Pharmaceuticals' stock fell 4.6% to $7.31, with trading volume down 12%. Analysts have mixed ratings, with an average 'Hold' and a $9.25 target. The company reported a ($0.34) EPS miss but a 147.6% revenue increase. Insiders sold shares, and institutional investors adjusted holdings, owning 89.06% of the stock.
2025 Informed: Healthtech predictions
AI's impact on healthcare by 2025 will focus on enhancing medical practices, improving clinical trials, advancing women’s health, and exploring quantum technology. Specialised AI tools, predictive healthcare triage, and data cooperatives will emerge, alongside advancements in drug discovery and at-home health monitoring devices.
RXRX Stock Surges with Promising Trials: What’s Next for Investors?
Recursion Pharmaceuticals Inc.'s stock rises 7.71% following promising Phase 1/2 trial results for REC-617 in solid tumors and the initiation of REC-1245 trials, showcasing AI-driven drug discovery potential despite financial losses.
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
Recursion Pharmaceuticals, an AI-focused biotech, could see significant progress in 2025. The company uses AI to accelerate drug discovery and development, potentially launching medicines faster and at lower costs. Collaborations with Nvidia and others, along with positive clinical trial results, suggest potential, though risks remain as no drugs are yet on the market.
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Recursion Pharmaceuticals, an AI-powered biotech, leverages AI for drug discovery, potentially revolutionizing medicine. Its merger with Exscientia enhances its platform, offering a promising pipeline of therapeutic candidates. However, financial losses and competitive landscape pose risks, making it too early to invest with conviction.
The 'compuchem'-AI showdown
Schrödinger, a computational chemistry company, resists AI hype in drug discovery, emphasizing physics-based methods. CEO Ramy Farid highlights AI's limitations, using it selectively with curated datasets. Schrödinger's approach focuses on molecular interactions, differentiating it from AI-only methods. The company has a successful track record, including cofounded firms and an internal drug pipeline.
Pharmaceutical industry and decarbonization: A difficult equation
The pharmaceutical industry must balance patient care with reducing environmental impact, accounting for 4.4% of global CO2 emissions. Strategies include optimizing the value chain, relocating manufacturing, and adopting renewable energy. Breakthrough innovations like AI and eco-design can accelerate drug development and reduce waste. Countries are setting goals for carbon neutrality, with the US aiming for 50% reduction by 2030 and the UK's NHS targeting neutrality by 2040. Collaboration among stakeholders is crucial for achieving these goals.
© Copyright 2025. All Rights Reserved by MedPath